Clinical Trials · NCT02461589
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 706
- Start date
- Sep 2015
- Locations
- 150 sites, 10 countries
- Primary endpoint
- Change in HbA1c (Glycosylated Haemoglobin)